Pharmacological approach to acute pancreatitis

Ulrich Christian Bang, Synne Semb, Camilla Nøjgaard, Flemming Bendtsen

Abstract

The aim of the present review is to summarize the current knowledge regarding pharmacological prevention and treatment of acute pancreatitis (AP) based on experimental animal models and clinical trials. Somatostatin (SS) and octreotide inhibit the exocrine production of pancreatic enzymes and may be useful as prophylaxis against Post Endoscopic retrograde cholangiopancreatography Pancreatitis (PEP). The protease inhibitor Gabexate mesilate (GM) is used routinely as treatment to AP in some countries, but randomized clinical trials and a meta-analysis do not support this practice. Nitroglycerin (NGL) is a nitrogen oxide (NO) donor, which relaxes the sphincter of Oddi. Studies show conflicting results when applied prior to ERCP and a large multicenter randomized study is warranted. Steroids administered as prophylaxis against PEP has been validated without effect in several randomized trials. The non-steroidal anti-inflammatory drugs (NSAID) indomethacin and diclofenac have in randomized studies showed potential as prophylaxis against PEP. Interleukin 10 (IL-10) is a cytokine with anti-inflammatory properties but two trials testing IL-10 as prophylaxis to PEP have returned conflicting results. Antibodies against tumor necrosis factor-alpha (TNF-α) have a potential as rescue therapy but no clinical trials are currently being conducted. The antibiotics beta-lactams and quinolones reduce mortality when necrosis is present in pancreas and may also reduce incidence of infected necrosis. Evidence based pharmacological treatment of AP is limited and studies on the effect of potent anti-inflammatory drugs are warranted.

INTRODUCTION

Acute pancreatitis (AP) is a localized inflammatory condition, which may extent to other organs. The etiology is usually excessive consumption of alcohol or gallstone disease, but in some cases iatrogenic following medication or endoscopic retrograde cholangiopancreatography (ERCP).

Only a few reviews summarizing the available pharmacological options for treating AP have been published despite various experimental and clinical testing of potential drugs[1]. The aim of the present review is to validate the current literature covering the pharmacological treatment of AP. The main focus is on human clinical trials but some animal experimental models have been included as well (Table 1). AP after ERCP [post-ERCP pancreatitis (PEP)] can be regarded as a clinical "experimental" model of AP and hence is subject to preventive measures. The studies of potentially prophylactic drugs to PEP are therefore included (Table 2).

PATHOPHYSIOLOGY

The pathobiological processes have primarily been investigated in experimental animal models and it is widely accepted that the acinar cells play a central role in the development of AP. The secretary acinar cells (SAC) contain zymogen precursors and the intra-acinar activation of digestive enzymes is a key event in the pathogenesis of AP. The molecular mechanism by which zymogen in AP fails to leave the SAC is unknown. Studies suggest a loss of the terminal actin web or a displacement of one of the SNARE membrane proteins, which regulate exocytosis[2].

The inflammatory response is partly caused by the release of chemokines from SAC, which is followed by recruitment of helper T lymphocytes and macrophages leading to pancreatic edema and accumulation of neutrophils. The systemic release of cytokines including major pro-inflammatory cytokines causes a systemic
response, which may include remote organs\(^3\). The inflammatory process is followed by interstitial edema and the disease will in 10%-15% of the cases progress to necrosis in parts of the pancreas and possible bacterial infection. During an attack of AP the microvascular circulation is affected, which compromises oxygenation of the tissue\(^5\).

The clinical manifestations of AP include upper abdominal pain and symptoms related to the systemic inflammatory response. In complicated cases with involvement of remote organ systems mortality is increased to 5% with ranges from 0% to 47% depending on the severity of the disease. The current treatment of AP is mainly supportive care using analgesics and relevant measures when other organs are involved. Enteral nutrition must be initiated as soon as possible and whenever patients are unable to eat, feeding tubes should be used. Supplementary treatment often involves antibiotics when an infection is suspected and surgery or enteral nutrition. Only articles in English were included. Earlier published reviews were manually examined for other relevant studies.

### METHODS

Published trials were identified on PubMed using the MeSH term “AP” in combination with the following MeSH terms: steroids, cortisone, hydrocortisone, corticosteroids, nitroglycerin (NGL), non-steroidal anti-inflammatory drugs (NSAID), celecoxib, COX-II, diclofenac, indomethacin, interleukin 10 (IL-10), tumor necrosis factor-alpha (TNF-α), infliximab, Remicade\(^®\), etanercept, adalimumab, Humira\(^®\), platelet activating-factor (PAF), lexipafant, antibiotics, somatostatin (SS), octreotide, Sandostatin\(^®\), probiotics, gabexate, nutrition. Only articles

### SS/octreotide

SS is a peptide hormone mainly produced in the gastrointestinal tract, where it has an inhibitory effect on gastric emptying, intestinal motility and intestinal blood flow. Furthermore, SS strongly inhibits the production of pancreatic enzymes, which has been the basis for using SS or its analogue octreotide as treatment for AP\(^9\).

Both experimental and clinical trials have been conducted with SS and octreotide, but no effect on the course of the disease has hitherto been demonstrated. Most of the clinical trials comprised only few patients and often patients with interstitial pancreatitis were included although this condition is self-limiting and does not require specific therapy\(^9\). The largest and best conducted study is a German prospective multicenter study with 302 patients from 32 hospitals with moderate to severe AP randomized to either octreotide or placebo. This study revealed no significant differences between the treatment groups with respect to mortality, rate of complications, surgical interventions or length of hospital stay\(^9\).

Several studies have examined SS or octreotide as prophylaxis to PEP. Various regimes have demonstrated a reduced incidence of PEP compared to placebo: SS administered as a bolus immediately after ERCP (4.4% \(vs\) 13.3%, \(P = 0.01\))\(^11\), SS given as a 12-h continuous infusion starting 30 min before ERCP (1.7% \(vs\) 9.8%, \(P < 0.05\))\(^12\) and octreotide in repeated injections starting 24 h prior to ERCP (2% \(vs\) 8.9%, \(P = 0.03\))\(^13\). It should be noted that these studies have a fairly high incidence of PEP in the placebo groups. Andriulli \textit{et al} have performed two similar

### Table 1 Pharmacological treatment of acute pancreatitis: Overview of drugs tested in animal experimental models and clinical trials

| Name               | Mechanism                                | Effect in animal models | Result in human trials |
|--------------------|------------------------------------------|-------------------------|------------------------|
| Somatostatin       | Inhibition of pancreatic secretion       | No reduced mortality    | No reduced mortality   |
| Octreotide         | Inhibition of pancreatic secretion       | No effect (divergent results) | No reduced mortality   |
| Gabexate mesilate  | Protease inhibitor                       | Reduced histology score | Maybe reduced mortality|
| N-acetyl-cysteine  | Reduction of oxidative stress            | Reduced severity        | No reduced mortality   |
| Nitrogen oxide     | Improvement of micro-circulation         | Reduced edema           | No published trials    |
| Steroids           | Non-specific anti-inflammatory           | Reduced mortality       | No published trials    |
| Interleukin-10     | Anti-inflammatory                        | Reduced mortality       | No published trials    |
| TNF-alpha antibody | Specific anti-inflammatory               | Reduced mortality       | No published trials    |
| PAF inhibitor      | Specific anti-inflammatory               | No reduced mortality    | No reduced mortality   |
| Antibiotics        | Antibacterial                            |                         | Reduced mortality      |
| Probiotics         | Prevention of colonization of the gut    |                         | No reduced mortality   |

### Table 2 Pharmacological prevention of PEP: Overview of drugs tested in clinical trials

| Name               | Mechanism                                | Incidence of PEP |
|--------------------|------------------------------------------|-------------------|
| Somatostatin       | Inhibition of pancreatic secretion       | No effect         |
| Octreotide         | Inhibition of pancreatic secretion       | Probably reduced  |
| Gabexate mesilate  | Protease inhibitor                       | No effect         |
| N-acetyl-cysteine  | Reduction of oxidative stress            | No effect         |
| Nitrogen oxide     | Improvement of micro-circulation         | No effect         |
| Steroids           | Non-specific anti-inflammatory           | No effect         |
| Interleukin-10     | Anti-inflammatory                        | Probably no effect|
| TNF-alpha antibody | Specific anti-inflammatory               | No published trials|
| Antibiotics        | Antibacterial                            | Reduced            |

www.wjgnet.com
large, double blind, multicenter, placebo-controlled trials using SS. They used a dosage of 750 micrograms SS as an infusion starting 30 min prior to ERCP, ending 2 h (SS = 183, placebo = 199) or 6 h (SS = 351, placebo = 395) after ERCP. The incidences of PEP in the placebo groups were 6.5% and 4.8% respectively and no advantageous effect of SS was observed[^14,^53].

The reports published during the years 2002 to 2006 have been summarized in a meta-analysis, which concluded that SS or octreotide have no effect as prophylaxis prior to ERCP[^38,^54]. However, this meta-analysis did not include the most recent trial from China with 832 patients. In this study, octreotide was administered as a combination of intravenous infusion and subcutaneous injections and the incidence of PEP in the treatment group (n = 414) and the placebo group (n = 418) was 2.42% and 5.26% respectively (P = 0.046)^[^17].

Octreotide and SS have thus been investigated in several clinical studies and may have an advantageous effect as prophylaxis prior to ERCP. Optimal dosage and cost-effectiveness still need to be elucidated.

**Protease inhibitor-Gabexate mesilate (GM)**

The intracellular activation of proteases is a mandatory step in the development of AP and the protease inhibitors could theoretically have an effect in the treatment of AP or as prophylaxis prior to ERCP. The first protease inhibitor, Aprotinin, was widely used in the 1960's but randomized trials could not demonstrate any beneficial effect[^6,^19]. GM is a synthetic protease inhibitor, which improve histology score in animal models of AP[^29].

In the 1980's several reports with a varying number of patients with AP (n = 42 to 223) have been published but none showed any advantage of GM[^21-^24]. Conversely Chen et al observed a significant improved survival in a randomized trial including 52 patients with severe AP who received GM (mortality 33% vs 8%)[^27]. A meta-analysis later concluded that GM may reduce the mortality in patients with moderate to severe pancreatitis, but the authors also noted that poor quality of the included randomized trials limits the power of this meta-analysis[^28].

Several papers from Japan report a reduced mortality rate in patients with necrotizing AP receiving GM as continuous regional arterial infusion (CRAI). However this conclusion is based merely on clinical observations and not placebo-controlled randomized trials[^33,^34].

Looking at the effect on PEP two large studies by Andriulli et al with in total 1172 patients did not reveal any beneficial effect of GM. These results are in conflict with an earlier study by Cavallini et al, who in a study of 418 patients observed a PEP incidence of 6% in the GM group and 14% in the placebo group (P = 0.009)^[^33]. However, a recent meta-analysis concludes that GM does not have an advantageous effect as prophylaxis to PEP[^38].

The question continues to be a matter of debate and based on their trial with 608 patients, Manes et al argue that high-risk patients may benefit from GM. They administered GM either before or after ERCP compared to a saline solution. The incidence of PEP was 9.4% in the placebo group, and significantly lower (P < 0.01) in the GM groups regardless of the time GM was administered (before ERCP 3.9%, after ERCP 3.4%)[^33].

**Antioxidants**

Oxidative stress most likely plays a major role in the early development of AP[^37] and several experimental animal models show a beneficial effect of anti-oxidative drugs[^38-^44]. In humans depletion of antioxidants is observed in AP[^45,^46] correlating to the severity of the disease[^47].

Therapy with antioxidants administered intravenously has been investigated in a prospective double-blind placebo controlled randomized trial on patients with predicted severe AP but no effect on mortality could be demonstrated[^48]. The prophylactic effect on the incidence of PEP was tested in two randomized prospective randomized trials with 256 and 106 patients, respectively. N-acetylcysteine (NAC) was administered before and after ERCP and both studies concluded that NAC was without any preventive effect[^49,^50]. Thus, there is no evidence for the use of NAC.

**NGL**

NGL is a donor of nitrogen oxide (NO), which causes vasodilatation and reduces cardiac preload. The main indication for using NGL is angina pectoris[^51].

Experimental animal models have shown reduced pancreatic edema when administering NO as an infusion[^52] but until now no clinical randomized trials using NGL in the treatment of AP have been published. As prophylaxis prior to ERCP three prospective randomized trials have evaluated NGL. NO induces periamppulary sphincter relaxation and dilation of the micro vascular vessels, which hypothetically improve pancreatic circulation and nutrition[^33].

Sudhindran et al observed in a study of 186 patients randomized to either NGL 2 mg sublingual 5 min prior to ERCP or placebo, an incidence of PEP in the NGL group of 8% compared to 18% (P < 0.05) in the placebo group[^54]. This finding was supported by Moreto et al who randomized 144 patients to either NGL as dermal patch or placebo, and found a significant reduction in the incidence of PEP (4% vs 16%, P < 0.05)^[^53]. Both studies have been criticized for having a surprisingly high incidence of PEP in the placebo groups[^54]. In a recently published prospective randomized trial of 318 patients the overall incidence of PEP was 7.5% and no significant difference between the NGL group and the placebo group was revealed[^57].

NGL has the optimal qualities as a prophylactic agent as it is cheap and easy to administer. However further trials are needed to determine its potential use as prophylaxis against PEP.

**Corticosteroids**

Corticosteroids are potent unspecific anti-inflammatory
drugs utilized in a variety of inflammatory diseases. Several case reports have suspected steroids of being the etiology to iatrogenic AP but a definite relationship has not been established.

In rat models of AP hydrocortisone has reduced mortality and blood cytokine levels. No human trials using steroids as treatment of AP have been published and attempts to show a beneficial effect of steroids as prophylaxis against PEP in prospective placebo-controlled trials have so far been disappointing. In 1999 De Palma et al randomized 539 patients to either placebo (n = 266) or hydrocortisone 100 mg (n = 273) administered intravenously prior to ERCP. The total incidence of PEP was 5.3% (n = 28) and no significant difference between the two groups could be demonstrated. In a Polish trial published in 2001, 300 patients received oral prednisone 40 mg, allopurinol 200 mg or placebo 15 h and 3 h prior to ERCP. The total incidence of PEP was 10.7% and no significant difference among the three groups was displayed. Sherman et al have confirmed these negative findings in an even larger prospective trial with 1115 patients.

Although steroids have the potential to inhibit the inflammatory cascade there is no evidence for the use of neither hydrocortisone nor prednisone as prophylaxis against PEP.

**NSAID**

NSAID have an analgesic as well as an anti-inflammatory effect. Most NSAID act as non-selective inhibitors of the enzyme COX which catalyses the formation of prostaglandins and thromboxane from arachidonic acid. NSAID are used for virtually every known inflammatory disease.

Salicylic acid and indomethacin have in isolated case reports been related to the development of AP as has the selective cyclooxygenase (COX)-2 inhibitor celecoxib.

Experimental animal models studying the effect of NSAID on AP have been contradictory and not revealed any effect on mortality.

The only randomized human study on the therapeutic effect of NSAID on AP has been conducted by Ebbehoj et al who included 30 patients randomized in two groups receiving either indomethacin suppositories 50 mg twice daily for 7 d or placebo. No difference in serum amylase or calcium was observed but patients in the indomethacin group demanded less opiate as analgesics during hospitalization. Mortality was not registered.

Two studies testing the prophylactic effect of indomethacin given prior to ERCP to prevent PEP have been published. Montano et al included 117 patients, who received either indomethacin suppositories 100 mg or placebo 2 h prior to ERCP. The incidence of PEP was 2.5% and 6.8% respectively but the difference was not significantly different. In a larger study from Iran 490 participants received 100 mg indomethacin suppositories or placebo and an incidence of PEP of 3.2% in the indomethacin group and 6.8% in the placebo group was observed. The difference was only borderline significant different (P = 0.06) and a post hoc analysis showed significant lower incidence of PEP in the subpopulation of patients who underwent pancreatectography. However this conclusion was hampered by the fact that the post hoc analysis was conducted on 10 subpopulations, which in general reduces the statistical power considerably.

Another NSAID, diclofenac, has been investigated in a study including 220 patients receiving either diclofenac suppositories 100 mg or placebo immediately after ERCP. PEP occurred with lower frequency in the group receiving diclofenac compared to the placebo group (6% vs 15%, P < 0.05).

The overall impression from placebo-controlled trials suggests a beneficial effect of NSAID used as prophylaxis against PEP. Both diclofenac and indomethacin can be administered easily as suppositories and are inexpensive drugs. Still, placebo controlled randomized trials with a larger sample size are needed to verify this promising effect.

**IL-10**

IL-10 is produced and released by the helper T cells and its primary effect is anti-inflammatory. Clinical observations have shown increased levels of IL-10 in the blood during AP but its role in the treatment of AP remains to be determined.

The effect of IL-10 on AP has been validated in two experimental studies which showed a reduced mortality.

No human study on the therapeutic effect of IL-10 has been conducted but the prophylactic effect of IL-10 on PEP has been evaluated in two randomized studies. No significant difference among the IL-10 and placebo-treated group was observed in a study with 200 patients receiving either recombinant IL-10 (8 μg/kg) or placebo (9% vs 11%, P = 0.65). A second study randomized 137 patients to placebo or IL-10 (4 μg/kg or 20 μg/kg) administered 30 min prior to ERCP. Overall incidence of PEP was 14% and a significant difference in the incidence among the three groups was noted (24%, 10%, and 7%). However the incidence of PEP in the placebo was remarkable high.

The results from these two published studies do not definitively support the use of IL-10 as prophylaxis against PEP.

**TNF-α**

During AP the serum level of TNF-α is elevated. The synthesis and release of TNF-α takes place in macrophages located in the pancreas. SAC may as well release TNF-α and do also express TNF-α receptors during AP. A possible relationship between genetic polymorphism and severity of AP has been established.

Blocking the TNF-α mediated inflammation with anti-TNF-α antibodies or pentoxifylline seems to have a beneficial effect on histology score and mortality in experimental animal models.

No data on humans has hitherto been published apart from a single case-report concerning a patient with interstitial pancreatitis. In this case, a male patient with severe bloody diarrhea due to segmental Crohn’s disease also showed signs of AP. Serum amylase was high and ultrasound and abdominal computer tomography (CT) scans revealed an edematous pancreas. Because of these
findings treatment with steroids and azathioprine was abandoned and instead a single infusion with infliximab 5 mg/kg was administered without complications. The patient's overall condition improved and serum amylase levels normalized[99].

Thus experimental data suggest a potential role of specific TNF-α inhibition in the treatment of AP, but high risk of bacterial infection during AP is a matter of concern. Infliximab has been evaluated in alcoholic hepatitis, another condition associated with a high risk of bacterial infection. The administration of prednisolone 40 mg daily and infliximab 10 mg/kg at wk 0, 2 and 4 showed an increased mortality due to infection and the study was terminated prematurely by the monitoring committee[108].

Hence clinical studies on AP must be carefully designed to evaluate the safety of infliximab or other specific TNF-α inhibitor.

**PAF**

PAF was discovered in the 1970’s and soon recognized to be an important inflammatory mediator[100]. Later studies with experimental pancreatitis revealed that PAF is released during AP[102] and induce AP when infused in arteries supplying the pancreas[103,104]. Experimental studies have shown a benefit from PAF inhibition with various antagonists on pancreatic edema and systemic inflammation as well as a decreased bacterial translocation[105-107].

As a consequence of the promising results with experimental AP different clinical studies have evaluated the effect of PAF inhibition. The first trial consisted of 83 patients with AP receiving lelipafant (n = 42) or placebo (n = 41). Lexipafant was administered intravenously (60 mg/d for 3 d) and follow-up was assessed for 5 d by Organ Failure Score (OFS). The investigators reported a greater reduction in OFS in the lelipafant group (0.905 vs 0.341, P = 0.048), but during the 5 d period mortality was unaffected[108]. These findings were confirmed in a second trial including only patients with severe AP. The participants received lelipafant (n = 27), 100 mg/d for 5-7 d or placebo (n = 23). In the treatment group a larger reduction in OFS was registered (1.42 vs 0.17, P = 0.003). Overall mortality was 18% with no difference between the groups[109]. The last study was published in 2001 and involved 286 patients with severe AP. Lexipafant (100 mg/d, n = 148) or placebo (n = 138) was administered for 7 d. No positive effect could be shown neither on OFS nor mortality[110]. It has been argued that data on the effect of lelipafant on mortality from experimental AP were warranted before initiation of human trials and the sponsor's communication of the result has been questionable[111]. After the termination of the clinical trials the lack of effect on mortality in experimental AP was acknowledged[112]. Randomized trials on sepsis were also disappointing[113,114] and inhibition of PAF in the treatment of AP has thus been abandoned.

**Antibiotics**

Antibiotics is used to prevent or treat infected necrosis in the pancreas and does not have potential to change the pathobiologic course of AP. Infected necrosis in pancreas is a major clinical problem during AP which severely deteriorate the prognosis[115,116]. Hence, administration of antibiotics to prevent infection has been evaluated in several randomized trials.

Sainio et al randomized 60 patients with necrotizing pancreatitis. The inclusion criteria were C-reactive protein > 120 mg/L and pancreatic necrosis verified by an abdominal CT scan. The treated group received infusion of cefuroxim 1.5 × 3 daily, while patients allocated to the control group only received antibiotics in case of clinical signs of infection. A significant higher mortality was registered in the control group compared to the cefuroxim group (23% vs 3%, P = 0.03)[117].

Pederzoli et al randomized 74 patients with CT verified pancreatic necrosis to receive either imipenem or placebo but no effect on mortality was registered[118]. In another prospective randomized study with 90 patients Nordback et al administered imipenem intravenously 1.0 g × 3 daily and found a reduced incidence of multigorgan failure compared to the control group (28% vs 76%, P = 0.0003) but no difference in mortality[119].

The studies described above are open-label trials. In 2004 Isenmann et al published a controlled double-blind study of 114 patients with CT verified necrotizing AP. The inclusion criteria were C-reactive protein > 150 mg/L and/or CT-verified pancreas necrosis. Placebo was compared to a combination of ciprofloxacin and metronidazole and if any complications occurred the treatment was converted to open conventional treatment. No difference in mortality or incidence of pancreas necrosis could be shown[120].

A Cochrane meta-analysis of 294 patients with CT-verified pancreas necrosis showed a reduced mortality in patients with necrotizing AP when beta-lactams and quinolones were administered intravenously as prophylaxis[121].

The subject continues to be a matter of debate and recommendations from major clinical associations have different approaches to this issue[122,123].

Studies on the effect of prophylactic antibiotics given prior to ERCP are limited. In a study by Rathy et al with 315 patients cephtazidime was administered intravenously prior to ERCP compared with a control group. They found reduced incidence of PEP and cholangitis in the treatment group (3% vs 9%, P = 0.009)[122]. However the study was not placebo-controlled and routine administration of antibiotics prior to ERCP cannot be recommended until randomized placebo controlled studies confirm this finding.

**Probiotics**

Intestinal permeability is increased during AP, which may facilitate translocation of bacteria from the intestinal lumen. Oral probiotics are living microorganisms that exert health benefits beyond those of inherent basic nutrition[123].

Olah et al conducted two prospective placebo controlled double-blinded studies of the therapeutic effect of probiotics to AP. The studies were published in 2002.
and 2007 including 45 and 62 patients with interstitial or severe AP. In the latter study reduced mortality in the probiotics groups was observed but the difference was not statistical significant[124,125].

CONCLUSION

As described in this review we only have limited evidence based pharmacological approaches when treating AP and none of these are curative. Several treatments including animal experimental studies have been tried in order to establish evidence for etiology based medical treatment (Tables 1 and 2). In Italy and Japan gabexate is used routinely with the aim to limit pancreatic auto-digestion, but as reported in this review there is no conclusive evidence for this approach.

Ocreotide may be considered as prophylaxis against PEP but high cost of this peptide hormone limits its potential in clinical practice. A much cheaper alternative is NSAID, which may be considered as prophylaxis against PEP.

Antibiotics are the drugs of choice when infection is evident. However, recommendations regarding the prevention of infected pancreatic necrosis are contradictory.

Various problems are encountered when designing clinical studies of AP. The low incidence of severe necrotizing AP constitutes a major problem, which demands multicenter studies. Another clinical challenge is the resemblance of AP to infection and before initialization of any experimental anti-inflammatory therapy bacterial infection must be refuted. This delays the start-up of the experimental protocol and causes bias as the patients in the meantime receive anti-bacterial treatment. A possible solution could be to administer antibiotics to all patients in combination with specific anti-inflammatory treatment or placebo.

In spite of these challenges the search for pharmacological treatment of AP must be sustained. As we present in this review experimental animal models support a potential effect of several anti-inflammatory drugs, which are candidates for randomized trials. The most interesting of these potential drugs is probably steroids, which are standard treatment of numerous inflammatory diseases but have never been investigated in the treatment of AP.

Because the outcome of the disease depends highly on the involvement of other organs, developing methods that inhibit the inflammatory signaling pathways presents a great potential. As new information regarding the inflammatory pathways continues to emerge from animal and clinical trials, specific treatment targeting these inflammatory processes should be considered. It is our opinion that animal models at this time support clinical trials with anti-TNF-α antibodies although a randomized trial must be designed not forgetting the safety issue.

REFERENCES

1. Lankisch PG, Lerch MM. Pharmacological prevention and treatment of acute pancreatitis: where are we now? Dig Dis Sci 2006; 24: 148-159
2. Pandol SJ, Saluja AK, Imrie CW, Banks PA. Acute pancreatitis: bench to the bedside. Gastroenterology 2007; 132: 1127-1151
3. Makhija R, Kingsnorth AN. Cytokine storm in acute pancreatitis. J Hepatobiliary Pancreat Surg 2002; 9: 401-410
4. Banks PA, Freeman ML. Practice guidelines in acute pancreatitis. Am J Gastroenterol 2006; 101: 2379-2400
5. Sherman S, Ruffolo TA, Hawes RH, Lehman GA. Complications of endoscopic sphincterotomy. A prospective series with emphasis on the increased risk associated with sphincter of Oddi dysfunction and nondilated bile ducts. Gastroenterology 1991; 101: 1068-1075
6. Freeman ML, DiSario JA, Nelson DB, Fennerty MB, Lee JG, Bjorkman DJ, Overby CS, Aas J, Ryan ME, Bochna GS, Shaw MJ, Snady HW, Erickson RV, Moore JP, Roel JP. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc 2001; 54: 425-434
7. Cheng CL, Sherman S, Watkins JL, Barnett J, Freeman M, Geenen J, Ryan M, Parker H, Frakes JT, Fogel EL, Silverman WB, Dua KS, Aliperi G, Yakshe P, Uzer M, Jones W, Goff J, Lazzell-Pennell L, Rashdan A, Temkit M, Lehman GA. Risk factors for post-ERCP pancreatitis: a prospective multicenter study. Am J Gastroenterol 2006; 101: 139-147
8. Katz MD, Erstad BL. Ocreotide, a new somatostatin analogue. Clin Pharm 1989; 8: 255-273
9. Cavallini G, Frulloni L. Somatostatin and octreotide in acute pancreatitis: the never-ending story. Dig Liver Dis 2001; 33: 192-201
10. Uhl W, Buchler MW, Malfertheiner P, Beger HG, Adler G, Gaus W. A randomised, double blind, multicentre trial of ocreotide in moderate to severe acute pancreatitis. Gut 1999; 45: 97-104
11. Poon RT, Yeung C, Liu CL, Lam CM, Yuen WK, Lo CM, Tang A, Fan ST. Intravenous bolus somatostatin after diagnostic cholangiopancreatography reduces the incidence of pancreatitis associated with therapeutic endoscopic retrograde cholangiopancreatography procedures: a randomised controlled trial. Gut 2003; 52: 1768-1773
12. Arvanitidis D, Anagnostopoulos GK, Giannopoulos D, Pantes A, Agaritisi R, Margantinis G, Tsisakos S, Sakorafas G, Kostopoulos P. Can somatostatin prevent post-ERCP pancreatitis? Results of a randomized controlled trial. J Gastroenterol Hepatol 2004; 19: 278-282
13. Thomopoulos KC, Pagoni NA, Vagenas KA, Margaritis VG, Theocharis GI, Nikolopoulou VN. Twenty-four hour prophylaxis with increased dosage of octreotide reduces the incidence of post-ERCP pancreatitis. Gastrointest Endosc 2006; 64: 726-731
14. Andriulli A, Clemente R, Solmi L, Terruzzi V, Suriani R, Sigilliito A, Leandro G, Leo P, De Maio G, Perri F. Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial. Gastrointest Endosc 2002; 56: 488-495
15. Andriulli A, Solmi L, Loperfido S, Leo P, Festa V, Belmonte A, Spriro F, Silla M, Forte G, Terruzzi V, Marengo G, Ciliberto E, Sabatino A, Monica F, Magnolia MR, Perri F. Prophylaxis of ERCP-related pancreatitis: a randomized, controlled trial of somatostatin and gabexate mesylate. Clin Gastroenterol Hepatol 2004; 2: 713-718
16. Andriulli A, Leandro G, Federici T, Ippolito A, Forlano R, Iacobellis A, Annese V. Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis. Gastrointest Endosc 2007; 65: 624-632
17. Li ZS, Pan X, Zhang WJ, Gong B, Zhi FC, Guo XG, Li PM, Fan ZN, Sun WS, Shen YZ, Ma SR, Xie WF, Chen MH, Li YQ. Effect of octreotide administration in the prophylaxis of post-ERCP pancreatitis and hyperamylasemia: A multicenter, placebo-controlled, randomized clinical trial. Am J Gastroenterol 2007; 102: 46-51
18. Morbidity of acute pancreatitis: the effect of aprotinin and glucagon. Gut 1980; 21: 334-339
Traynell JE, Rigby CC, Talbot CH, Duncan EH. A controlled trial of Trasylol in the treatment of acute pancreatitis. Br J Surg 1974; 61: 177-182

Wieder JR Jr., Renner KG, Grendell JH, Niederau C, Ferrell LD. Gabexate mesylate (FOY) protects against ceruleide-induced acute pancreatitis in the rat. Pancreas 1987; 2: 18-186

Tynpfer N, Rosch W. [Effect of secretin and gabexate-mesylate (synthetic protease inhibitor) on serum amylase level after ERCP] Z Gastroenterol 1982; 20: 688-693

Freise J, Melzer P, Schmidt FW, Horbach L. [Gabexate mesylate in the treatment of acute pancreatitis. Results of a Hannover multicenter double-blind study with 50 patients] Z Gastroenterol 1986; 24: 200-211

Yang CY, Chang-Chien CS, Liaw YF. Controlled trial of protease inhibitor gabexate mesylate (FOY) in the treatment of acute pancreatitis. Pancreas 1987; 2: 698-700

Harada H, Miyake H, Ochi K, Tanaka J, Kimura I. Clinical trial with a protease inhibitor gabexate mesylate in acute pancreatitis. Int J Pancreatol 1991; 9: 75-79

Valdderama R, Perez-Mateo M, Navarro S, Vazquez N, Sanjose L, Adrion MJ, Estruch J, Multicenter double-blind trial of gabexate mesylate (FOY) in unsolicited patients with acute pancreatitis. Digestion 1992; 51: 65-70

Buchler M, Malfertheiner P, Uhl W, Scholmerich J, Stockmann F, Adler G, Gaus W, Rolle K, Beger HG. Gabexate mesylate in human acute pancreatitis. German Pancreatitis Study Group. Gastroenterology 1993; 104: 1165-1170

Chen HM, Chen JC, Hwang TL, Jan YY, Chen MF. Prospective and randomized study of gabexate mesylate for the treatment of severe acute pancreatitis with organ dysfunction. Hepatogastroenterology 2000; 47: 1147-1150

Seta T, Noguchi Y, Shimada T, Shikata S, Fukui T. Treatment of acute pancreatitis with protease inhibitors: a meta-analysis. Eur J Gastroenterol Hepatol 2004; 16: 1287-1293

Takeda K, Matsuno S, Sunamura M, Kakugawa Y. Continuous regional arterial infusion of protease inhibitor and antibiotics in acute necrotizing pancreatitis. Am Surg 1996; 171: 394-398

Takeda K, Yamachi J, Shibuya K, Sunamura M, Mikami Y, Matsuno S. Benefit of continuous regional arterial infusion of protease inhibitor and antibiotic in the management of acute necrotizing pancreatitis. Pancreatology 2001; 1: 668-673

Cavallini G, Tittobello A, Fridolli L, Masci E, Mariana A, Di Francesco V. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy--Italian Group. N Engl J Med 1986; 315: 919-923

Zheng M, Chen Y, Yang X, Li J, Zhang Y, Zong Q. Gabexate in the prophylaxis of post-ERCP pancreatitis: a meta-analysis of randomized controlled trials. BMC Gastroenterol 2007; 7: 6

Manes G, Ardizzone S, Lombardi G, Uomo G, Pieranimo O, Porro GB. Efficacy of postprocedure administration of gabexate mesylate in the prevention of post-ERCP pancreatitis: a randomized, controlled, multicenter study. Gastrointest Endosc 2007; 65: 982-987

Whitcomb DC. Clinical practice. Acute pancreatitis. N Engl J Med 2006; 354: 2142-2150

Otsuki M, Hirota M, Arata S, Koizumi M, Kawa S, Kamisawa T, Takeda K, Mayumi T, Kitagawa M, Itô T, Inui K, Shimosegawa T, Tanaka S, Kataoka K, Saisho H, Okazaki K, Kuroda Y, Sawabu N, Takeyama Y. Consensus of primary care in acute pancreatitis in Japan. World J Gastroenterol 2006; 12: 3314-3323

Pelagotti F, Cecchi M, Messori A. Use of gabexate mesylate in Italian hospitals: a multicentre observational study. J Clin Pharmac Ther 2003; 28: 191-196

Sweiry JH, Mann GE. Role of oxidative stress in the pathogenesis of acute pancreatitis. Scand J Gastroenterol Suppl 1996; 219: 10-15

Neuschwander-Tetri BA, Ferrell LD, Sukhabote RJ, Grendell JH. Glutathione monoethyl ester ameliorates caerulein-induced pancreatitis in the mouse. J Clin Invest 1992; 89: 109-116

Demols A, Van Laethem JL, Quertinnont E, Legros F, Louis H, Le Moine O, Deviere J. N-acetylcysteine decreases severity of acute pancreatitis in mice. Pancreas 2000; 20: 161-169

Sevillano S, De la Mano AM, De Dios I, Ramudo L, Manso MA. Major pathological mechanisms of acute pancreatitis are prevented by N-acetylcysteine. Digestion 2003; 68: 34-40

Mamcu S, Alihan E, Turkyl Imsaz S, Kural BV, Ercin C, Kayloncu NI. Effects of N-acetylcysteine on acute necrotizing pancreatitis in rats. Eur Surg Res 2005; 37: 173-178

Ramudo L, Manso MA, Vicente S, De Dios I. Pro- and anti-inflammatory response of acinar cells during acute pancreatitis. Effect of N-acetyl cysteine. Cytokine 2005; 32: 125-131

Esrefoglu M, Gol M, Ates B, Yilmaz I. Ultrastructural clues for the protective effect of ascorbic acid and N-acetylcysteine against oxidative damage on caerulein-induced pancreatitis. Pancreatology 2006; 6: 477-485

Manso MA, Ramudo L, De Dios I. Extrapancreatic organ impairment during acute pancreatitis induced by bile-pancreatic duct obstruction. Effect of N-acetylcysteine. Int J Exp Pathol 2007; 88: 343-349

Scott P, Bruce C, Schofield D, Shiel N, Braganza JM, McCloy RF. Vitamin C status in patients with acute pancreatitis. Br J Surg 1993; 80: 750-754

Braganza JM, Scott P, Bilton D, Schofield D, Chaloner C, Shiel N, Hunt LP, Bottiglieri T. Evidence for early oxidative stress in acute pancreatitis. Clues for correction. Int J Pancreatol 1995; 17: 69-81

Bonham MJ, Abu-Zidan FM, Simovic MO, Sluis KB, Wilkinson A, Winterbourn CC, Windsor JA. Early ascorbic acid depletion is related to the severity of acute pancreatitis. Br J Surg 1999; 86: 1296-1301

Siriwardena AK, Mason J, Balachandra S, Bagul A, Galloway S, Formela L, Hardman JG, Jamdar S. Randomised, double blind, placebo controlled trial of intravenous antioxidant (N-acetylcysteine, selenium, vitamin C) therapy in severe acute pancreatitis. Gut 2007; 56: 1439-1444

Katsinelos P, Kountouras J, Paroutoglou G, Beltis A, Mimidis K, Zavos C. Intravenous N-acetylcysteine does not prevent post-ERCP pancreatitis. Gastrointest Endosc 2005; 62: 105-111

Milewski J, Rydzewska G, Degowska M, Kierzkiewicz M, Rydzewski A. N-acetylcysteine does not prevent post-endoscopic retrograde cholangiopancreatography hyperamylasemia and acute pancreatitis. World J Gastroenterol 2006; 12: 3751-3755

Sorkin EM, Brogden RN, Romankiewicz J A. Intravenous glyceryl trinitrate (nitroglycerin). A review of its pharmacological properties and therapeutic efficacy. Drugs 1993; 45: 295-315

Werner J, Rivera J, Fernandez-del Castillo C, Lewandowski K, Adric C, Rattner DW, Warshaw AL. Differing roles of nitric oxide in the pathogenesis of acute edematous versus necrotizing pancreatitis. Surgery 1997; 121: 23-30

Wehrmann T, Schmitt N, Stergiou N, Caspary WF, Seifert H. Topical application of nitrates onto the papilla of Vater: manometric and clinical results. Endoscopy 2001; 33: 323-328

Sudhindran S, Bromwich E, Edwards PR. Prospective randomized double-blind placebo-controlled trial of glyceryl trinitrate in endoscopic retrograde cholangiopancreatography-induced pancreatitis. Br J Surg 2001; 88: 1178-1182

Moreto M, Zaballa M. Prospective randomized double-blind placebo-controlled trial of glyceryl trinitrate in endoscopic retrograde cholangiopancreatography-induced pancreatitis. Br J Surg 2002; 89: 628; author reply 629

Curlidharaan V, Jan P. Pharmacologic prevention of post-ERCP pancreatitis: is nitroglycerin a sangreal? Gastrointest Endosc 2006; 64: 358-360

Kaffes AJ, Bourke MJ, Ding S, Alruhaia A, Wkan V, Williams SJ. A prospective, randomized, placebo-controlled trial of transfersomal glyceryl trinitrate in ERCP: effects on technical success and post-ERCP pancreatitis. Gastrointest Endosc 2006; 64: 351-357

Bourne MS, Dawson H. Acute pancreatitis complicating prednisolone therapy. Lancet 1958; 2: 1209-1210

Boruchowicz A, Gallon P, Foissey D, Gower P, Gamblin C, Cuingnet P, Maunoury V, Cortot A, Colombel JF. [Acute...
pancreatitis associated with corticosteroid treatment in Crohn's disease] Gastroenterol Clin Biol 2003; 27: 560-561.

60 Khanna S, Kumar A. Acute pancreatitis due to hydrocortisone in a patient with ulcerative colitis. J Gastroenterol Hepatol 2003; 18: 110-111.

61 Gloob B, Uhl W, Tscholakov O, Roggo A, Muller CA, Worni M, Buchler MW. Hydrocortisone treatment of early SIRS in acute experimental pancreatitis. Dig Dis Sci 2001; 46: 2154-2161.

62 Lazar G Jr, Varga J, Lazar G, Duda E, Takacs T, Balogh A, Lonovics J. The effects of glucocorticoids and a glucocorticoid antagonist (RU 38486) on experimental acute pancreatitis in rat. Acta Chir Hung 1997; 35: 190-193.

63 De Palma GD, Catanzano C. Use of corticosteroids in the prevention of post-ERCP pancreatitis: results of a controlled prospective study. Am J Gastroenterol 1999; 94: 982-985.

64 Budzynska A, Marek T, Nowak A, Kaczor R, Nowakowska-Dulawa E. A prospective, randomized, placebo-controlled trial of prednisone and allopurinol in the prevention of ERCP-induced pancreatitis. Endoscopy 2001; 33: 766-772.

65 Sherman S, Blaut U, Watkins JL, Barnett J, Freeman M, Geenen J, Ryan M, Parker H, Frakes JT, Vogel EL, Silverman WB, Dua KS, Aliperti G, Yakshe P, Uzer M, Jones W, Goff J, Earle D, Temkit M, Lehman GA. Does prophylactic administration of corticosteroid reduce the risk and severity of post-ERCP pancreatitis: a randomized, prospective, multicenter study. Gastrointest Endosc 2003; 58: 23-29.

66 Sussman S. Severe salicylism and acute pancreatitis. Calif Med 1963; 99: 29-32.

67 Guerra M. Toxicity of indomethacin. Report of a case of acute pancreatitis. JAMA 1967; 200: 552-553.

68 Memis D, Akalin E, Yucel T. Indomethacin-induced pancreatitis: a case report. JOP 2005; 6: 344-347.

69 Amaravadi RK, Jacobson BC, Solomon DH, Fischer MA. Acute pancreatitis associated with rofecoxib. Am J Gastroenterol 2002; 97: 1077-1078.

70 Nind G, Selby W. Acute pancreatitis: a rare complication of celecoxib. Intern Med J 2002; 32: 624-625.

71 Baciewicz AM, Sokos DR, King TJ. Acute pancreatitis associated with celecoxib. Ann Intern Med 2000; 132: 680.

72 Carrillo-Jimenez R, Nurnberger M. Celecoxib-induced acute pancreatitis and hepatitis: a case report. Arch Intern Med 2000; 160: 553-554.

73 Alhan E, Kaloyoncu NI, Ercin C, Kural BV. Effects of the celecoxib on diet-induced acute pancreatitis in mice. Inflammation 2004; 28: 303-309.

74 Coelle EF, Maldonado AH, Elashoff J, Lewin K, Taylor JL. Effects of prostaglandin and indomethacin on diet-induced acute pancreatitis in mice. Gastroenterology 1983; 85: 1307-1312.

75 de Almeida JL, de Almeida JL, Garcia CJ, Gonzalez OA, Fuentes OC, Davalos CC, Rodriguez L, X. Prevention of hyperamilasemia and pancreatitis after endoscopic retrograde cholangiopancreatography with rectal administration of indomethacin. Rev Gastroenterol Mex 2006; 71: 262-268.

76 Sotoudehmanesh R, Rabbani M, Gholam Rezaee S, Ainechi S, Maboolas B, Nouraei M. Indomethacin may reduce the incidence and severity of acute pancreatitis after ERCP. J Gastroenterol 2007;102: 978-983.

77 Wagah MS, Sherman S. Indomethacin for post-ERCP pancreatitis: Hypothesis: another attempt at the Holy Grail. Am J Gastroenterol 2007; 102: 984-986.

78 Murray B, Carter R, Imrie C, Evans S, O'Suilleabain C. Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography. Gastroenterology 2003; 124: 1786-1791.

79 Berney T, Gaushe Y, Robertson J, Nemes G, Vermeulen B, Moore P. Serum profiles of interleukin-6, interleukin-8, and interleukin-10 in patients with severe and mild acute pancreatitis. Pancreas 1999; 18: 371-377.

80 Pizzelli R, Billi P, Miniero R, Barakat B. Serum interleukin-10 in human acute pancreatitis. Dig Dis Sci 1997; 42: 1469-1472.

81 Kusske AM, Romione AJ, Ashley SW, McFadden DW, Reber HA. Interleukin-10 prevents death in lethal necrotizing pancreatitis in mice. Surgery 1996; 120: 284-288; discussion 289.

82 Romione AJ, Kusske AM, Reber HA, Ashley SW, McFadden DW. Interleukin-10 reduces circulating levels of serum cytokines in experimental pancreatitis. J Gastrointest Surg 1997; 1: 159-165; discussion 165-166.

83 Dumot JA, Conwell DL, Zuccaro G Jr, Vargo JJ, Shay SS, Eaton KA, Ponsky JL. A randomized, double blind study of interleukin 10 for the prevention of ERCP-induced pancreatitis. Am J Gastroenterol 2001; 96: 2098-2102.

84 Deviere J, Le Moine O, Van Laethem JL, Eisendrath P, Ghilain A, Severs N, Cohard M. Interleukin 10 reduces the incidence of pancreatitis after therapeutic endoscopic retrograde cholangiopancreatography. Gastroenterology 2001; 120: 498-505.

85 Kaufmann P, Tilz GP, Lueger A, Demel U. Elevated plasma levels of soluble tumor necrosis factor receptor (sTNF-Rp60) reflect severity of acute pancreatitis. Intensive Care Med 1997; 23: 841-848.

86 Reivet FG, Emilie D, Galanaud P. Pro- and anti-inflammatory cytokines during acute severe pancreatitis: an early and sustained response, although unpredictable of death. Parisian Study Group on Acute Pancreatitis. Crit Care Med 1999; 27: 749-755.

87 Vaccaro MI, Rosello A, Gardos D, Calvo EL, Ferreria M, Iovanna JL, Lanosa G. Pancreatic acinar cells submitted to stress activate TNF-alpha gene expression. Biochem Biophys Res Commun 2000; 268: 485-490.

88 Gukovska AS, Gukovski I, Zaninovic V, Song M, Sandoval D, Gukovski S, Pandol SJ. Pancreatic acinar cells produce, release, and target to tumor necrosis factor-alpha. Role in regulating cell death and pancreatitis. J Clin Invest 1997; 100: 1853-1862.

89 Ramudo L, Manso MA, Sevillard S, de Dios I. Kinetic study of TNF-alpha production and its regulatory mechanisms in acinar cells during acute pancreatitis induced by bile-pancreatic duct obstruction. J Pathol 2005; 206: 9-16.

90 Balog A, Gyulai Z, Boros LG, Farkas G, Takacs T, Lonovics J, Mandi Y. Polymorphism of the TNF-alpha, HSP70-2, and CD14 genes increases susceptibility to severe acute pancreatitis. Pancreas 2005; 30: e46-e50.

91 Hughes CB, Gaber LW, Mohey el-Din AB, Grewal HP, Koth M, Mann L, Gaber AO. Inhibition of TNF alpha improves survival in an experimental model of acute pancreatitis. Am Surg 1996; 62: 8-13.

92 Chen D, Wang W, Wang J. Influence of anti-TNF alpha monoclonal antibody on intestinal barrier in rats with acute pancreatitis. Chin Med Sci J 2000; 15: 257.

93 Malleo G, Mazzon E, Genovese T, Di Paola R, Muia C, Centorrino T, Sirovera AD, Cuzzocrea S. Etanercept attenuates the development of cerulein-induced acute pancreatitis in mice: a comparison with TNF-alpha genetic deletion. Shock 2007; 27: 542-547.

94 Ramudo L, Manso MA, Sevillano S, de Dios I. Kinetic study of TNF-alpha production and its regulatory mechanisms in acinar cells during acute pancreatitis induced by bile-pancreatic duct obstruction. J Pathol 2005; 206: 9-16.

95 Pereda J, Sabater L, Cassinello N, Gomez-Cambronero L, Closa D, Folch-Puy E, Aparisi L, Calvete J, Cerda M, Lledo A. Vina J, Sastre J. Effect of simultaneous inhibition of TNF-alpha production and xanthine oxidase in experimental acute pancreatitis: the role of nitrogen activated protein kinase. Ann Surg 2004; 230:108-116.

96 Triantafillidis JK, Cheracakis P, Hereti IA, Argyros N, Karra
E. Acute idiopathic pancreatitis complicating active Crohn's disease: favorable response to infliximab treatment. Am J Gastroenterol 2000; 95: 3334-3336

100 Naveau S, Chollet-Martin S, Dharancy S, Mathurin P, Jouet P, Picquet MA, Davion T, Oberti F, Broet P, Emilie D. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 2004; 39: 1390-1397

101 Benveniste J, Henson PM, Cochrane CG. Leukocyte-dependent histamine release from rabbit platelets. The role of IgE, basophils, and a platelet-activating factor. J Exp Med 1972; 136: 1356-1377

102 Kald B, Kald A, Ibane I, Tagesson C. Release of platelet-activating factor in acute experimental pancreatitis. Pancreas 1993; 8: 440-442

103 Emanuelli G, Montruccchio G, Gaia E, Dughera L, Corvetti G, Gubetta L. Experimental acute pancreatitis induced by platelet activating factor in rabbits. Am J Pathol 1989; 134: 315-326

104 Yotsumoto F, Manabe T, Yoshitomi S. Platelet-activating factor involvement in the aggravation of acute pancreatitis in rabbits. Digestion 1994; 55: 260-267

105 Jancar S, De Giacobi G, Mariano M, Mencia-Huerta JM, Sirois P, Braquet P. Immune complex induced pancreatitis: effect of BN 52021, a selective antagonist of platelet-activating factor. Prostaglandins 1988; 35: 757-770

106 Dabrowski A, Gabryelewicz A, Chyczewski L. The effect of platelet activating factor antagonist (BN 52021) on cerulein-induced acute pancreatitis with reference to oxygen radicals. Int J Pancreatol 1991; 8: 1-11

107 Tomaszewska R, Dembinski A, Warzecha Z, Banas M, Konturek SJ, Stachura J. Platelet activating factor (PAF) inhibitor (TCV-309) reduces caerulein- and PAF-induced pancreatitis. A morphologic and functional study in the rat. J Physiol Pharmacol 1992; 43: 345-352

108 Kingsnorth AN, Galloway SW, Formela LJ. Randomized, double-blind phase II trial of Lexipafant, a platelet-activating factor antagonist, in human acute pancreatitis. Br J Surg 1995; 82: 1414-1420

109 McKay CJ, Curran F, Sharpes C, Baxter JN, Imrie CW. Prospective placebo-controlled randomized trial of lepinafant in predicted severe acute pancreatitis. Br J Surg 1997; 84: 1239-1243

110 Johnson CD, Kingsnorth AN, Imrie CW, McMahon MJ, Neoptolemos JP, McKay C, Toh SK, Skaffe P, Leeder PC, Wilson P, Larvin M, Curtis LD. Double blind, randomised, placebo controlled study of a platelet activating factor antagonist, lepinafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis. Gut 2001; 48: 62-69

111 Abu-Zidan FM, Windsor JA. Lexipafant and acute pancreatitis: a critical appraisal of the clinical trials. Eur J Surg 2002; 168: 215-219

112 Rivera JA, Werner J, Warshaw AL, Lewandrowski KB, Rattner DW, Fernandez del Castillo C. Lexipafant fails to improve survival in severe necrotizing pancreatitis in rats. Int J Pancreatol 1998; 23: 101-106

113 Suputtamongkol Y, Intaransongpia S, Smith MD, Angus B, Chaowagul W, Permpikul C, Simpson JA, Leelarasamee A, Curtis L, White NJ. A double-blind placebo-controlled study of an infusion of lepinafant (Platelet-activating factor receptor antagonist) in patients with severe sepsis. Antimicrob Agents Chemother 2000; 44: 693-696

114 Vincent JL, Spapen H, Bakker J, Webster NR, Curtis L. Phase II multicenter clinical study of the platelet-activating factor receptor antagonist BB-882 in the treatment of sepsis. Crit Care Med 2000; 28: 638-642

115 Beger HG, Bittner R, Block S, Buchler M. Bacterial contamination of pancreatic necrosis. A prospective clinical study. Gastroenterology 1986; 91: 433-438

116 Isenmann R, Rau B, Beger HG. Bacterial infection and extent of necrosis are determinants of organ failure in patients with acute necrotizing pancreatitis. Br J Surg 1999; 86: 1020-1024

117 Sainio V, Kemppainen E, Puolakkainen P, Taavitsainen M, Kivisari L, Valtonen V, Haapiainen R, Schroder T, Kivilaakso E. Early antibiotic treatment in acute necrotising pancreatitis. Lancet 1995; 346: 663-667

118 Pedezzoli P, Bassi C, Vesentini S, Campedelli A. A randomized multicenter clinical trial of antibiotic prophylaxis of septic complications in acute necrotizing pancreatitis with imipenem. Surg Gynecol Obstet 1993; 176: 480-483

119 Nordback I, Sand J, Saaristo R, Paajanen H. Early treatment with antibiotics reduces the need for surgery in acute necrotizing pancreatitis--a single-center randomized study. J Gastrointest Surg 2001; 5: 113-118; discussion 118-120

120 Isenmann R, Runzi M, Kron M, Kahl S, Kraus D, Jung N, Maier L, Malfertheiner P, Goebell H, Beger HG. Prophylactic antibiotic treatment in patients with predicted severe acute pancreatitis: a placebo-controlled, double-blind trial. Gastroenterology 2004; 126: 997-1004

121 Villatoro E, Bassi C, Larvin M. Antibiotic therapy for prophylaxis against infection of pancreatic necrosis in acute pancreatitis. Cochrane Database Syst Rev 2006: CD002941

122 Raty S, Sand J, Pulkkinen M, Matikainen M, Nordback I. Post-ERCP pancreatitis: reduction by routine antibiotics. J Gastrointest Surg 2001; 5: 339-345; discussion 345

123 Guarnier M, Malagelada JR. Gut flora in health and disease. Lancet 2003; 362: 512-519

124 Olah A, Belagyi T, Issekutz A, Gamal ME, Bengmark S. Randomized clinical trial of specific lactobacillus and fibre supplement to early enteral nutrition in patients with acute pancreatitis. Br J Surg 2002; 89: 1103-1107

125 Olah A, Belagyi T, Poto L, Romics I, Jr, Bengmark S. Symbiotic control of inflammation and infection in severe acute pancreatitis: a prospective, randomized, double-blind study. Hepatogastroenterology 2007; 54: 990-994